Summary
The response’s interpretation of the label is largely consistent for the contraindication in patients with personal/family history of MTC or MEN 2, but it partially overreaches by characterizing a human C-cell tumor/MTC risk as if it is established, whereas the label states human relevance/risk is unknown.
Category Scores
Accurate Statements
ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
4 CONTRAINDICATIONS: contraindicated in personal/family history of MTC or MEN 2.
The label states it is unknown whether ZEPBOUND causes thyroid C-cell tumors, including MTC, in humans.
5.1 Risk of Thyroid C-Cell Tumors: “It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including MTC, in humans...”
Overstatement is a potential issue because the label says human relevance is unknown rather than confirmed.
5.1 Risk of Thyroid C-Cell Tumors: human relevance not determined/unknown; label does not affirm confirmed human causation.
Unsupported Statements
“ZEPBOUND/tirzepatide has a thyroid C-cell tumor (including MTC) risk in humans and should be avoided/contraindicated...”
The label supports that rodent thyroid C-cell tumors occurred and that human relevance is unknown, not that there is established human C-cell tumor/MTC risk.
Contradictions
Important Omissions
A precise label-consistent phrasing that distinguishes contraindication (MTC/MEN 2) from the uncertainty about human causation (human relevance unknown).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response correctly cites the contraindication for MTC/MEN 2, but it partially overstates human risk/causation. This could mislead users about the certainty of human tumor risk beyond what the label states.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Human thyroid C-cell tumor/MTC risk is implied as established, but the label states the human relevance is unknown.
Suggested Improvement
Rephrase to: “ZEPBOUND is contraindicated in patients with personal/family history of MTC or MEN 2. In rats, tirzepatide caused thyroid C-cell tumors, but it is unknown whether ZEPBOUND causes such tumors in humans (including MTC).”